Abstract
Malaria remains a globally prevalent infectious disease that leads to significant morbidity and mortality. While there are a number of drugs approved for its treatment, drug resistance has compromised most of them, making the development of new drugs for the treatment and prevention of malaria essential. The completion of the Plasmodium falciparum genome and a growing understanding of parasite biology are fueling the search for novel drug targets. Despite this, few targets have been chemically validated in vivo. The pyrimidine biosynthetic pathway illustrates one of the best examples of successful identification of anti-malarial drug targets. This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery. Several chemical scaffolds have been identified by high throughput screening as potent inhibitors of PfDHODH and these show strong selectivity for the malarial enzyme over that from the human host. Potent activity against parasites in whole cell models with good correlation between activity on the enzyme and the parasite have also been observed for a number of the identified series. Lead optimization of a triazolopyrimidine-based series has identified an analog with prolonged plasma exposure, that is orally bioavailable, and which shows good efficacy against the in vivo mouse model of the disease. These data provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy. The challenge remains to identify compounds with the necessary combination of potency and metabolic stability to allow identification of a clinical candidate.
Keywords: Malaria, Plasmodium, pyrimidine biosynthesis, dihydroorotate dehydrogenase, drug discovery
Infectious Disorders - Drug Targets
Title: Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy
Volume: 10 Issue: 3
Author(s): Margaret A. Phillips and Pradipsinh K. Rathod
Affiliation:
Keywords: Malaria, Plasmodium, pyrimidine biosynthesis, dihydroorotate dehydrogenase, drug discovery
Abstract: Malaria remains a globally prevalent infectious disease that leads to significant morbidity and mortality. While there are a number of drugs approved for its treatment, drug resistance has compromised most of them, making the development of new drugs for the treatment and prevention of malaria essential. The completion of the Plasmodium falciparum genome and a growing understanding of parasite biology are fueling the search for novel drug targets. Despite this, few targets have been chemically validated in vivo. The pyrimidine biosynthetic pathway illustrates one of the best examples of successful identification of anti-malarial drug targets. This review focuses on recent studies to exploit the fourth enzyme in the de novo pyrimidine biosynthetic pathway of P. falciparum, dihydroorotate dehydrogenase (PfDHODH), as a new target for drug discovery. Several chemical scaffolds have been identified by high throughput screening as potent inhibitors of PfDHODH and these show strong selectivity for the malarial enzyme over that from the human host. Potent activity against parasites in whole cell models with good correlation between activity on the enzyme and the parasite have also been observed for a number of the identified series. Lead optimization of a triazolopyrimidine-based series has identified an analog with prolonged plasma exposure, that is orally bioavailable, and which shows good efficacy against the in vivo mouse model of the disease. These data provide strong evidence that PfDHODH is a validated target for the identification of new antimalarial chemotherapy. The challenge remains to identify compounds with the necessary combination of potency and metabolic stability to allow identification of a clinical candidate.
Export Options
About this article
Cite this article as:
A. Phillips Margaret and K. Rathod Pradipsinh, Plasmodium Dihydroorotate Dehydrogenase: A Promising Target for Novel Anti-Malarial Chemotherapy, Infectious Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187152610791163336
DOI https://dx.doi.org/10.2174/187152610791163336 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PPARs in Diseases: Control Mechanisms of Inflammation
Current Medicinal Chemistry Nucleic Acids Modulate Autoimmunity Through Nucleic-Acid-Specific Toll-Like Receptors
Current Medicinal Chemistry Neddylation Pathway as a Novel Anti-cancer Target: Mechanistic Investigation and Therapeutic Implication
Anti-Cancer Agents in Medicinal Chemistry CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology Atorvastatin Sensitises Vascular Smooth Muscle Cells, but not Endothelial Cells, to TNF-α-induced Cell Death
Current Pharmaceutical Design Patent Selections:
Recent Patents on Chemical Engineering Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Current Stem Cell Research & Therapy Heparanase: Structure, Biological Functions, and Inhibition by Heparin-Derived Mimetics of Heparan Sulfate
Current Pharmaceutical Design Amyloid Beta Protein as a Marker or Risk Factor of Alzheimers Disease
Current Alzheimer Research Prostaglandin H Synthases and their Importance in Chemical Toxicity
Current Drug Metabolism The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Is there a Link between Vitamin B and Multiple Sclerosis?
Medicinal Chemistry Potential Therapeutic Application of the Association of Vitamins C and K3 in Cancer Treatment
Current Medicinal Chemistry Bioactive Cyclohexenones: A Mini Review
Current Bioactive Compounds Preface
Current Proteomics